Last reviewed May 10, 2026
Quick answer: The "window of opportunity" for starting HRT is under 60 OR within 10 years of menopause onset. Inside that window, the cardiovascular profile is net favorable (Hodis 2016 ELITE; Manson 2017 WHI follow-up). Outside it, the math shifts — neutral-to-negative cardiovascular signal, less bone benefit relative to the risk profile. You don't have to wait for menopause to start; perimenopausal women with significant vasomotor or quality-of-life symptoms qualify. The right time to start HRT is when symptoms warrant AND you are inside the timing window — not when an outdated rule says you've earned it.
The 60-second version
If you're 47 with symptoms and a doctor saying "come back later" — read this
You're 47. You have hot flashes, sleep that breaks at 3 a.m. for no reason, brain fog at work that wasn't there two years ago, and a doctor who looked at you for six minutes and said "come back when you've stopped having periods for a year." That advice is outdated. The science behind when to start HRT moved on more than a decade ago — and most of the women searching this question at midnight on their phones don't realize they are already inside the window of opportunity, with a mainstream-medicine green light from the 2022 NAMS Position Statement and the 2015 Endocrine Society Guideline.
Most articles about when to start HRT get the framework wrong in one of two directions. They either tell you to "wait until your symptoms are bad enough" — which leaves you sitting through the most volatile-estrogen phase of the transition with no treatment. Or they tell you to "start as early as possible" — which oversells HRT to perimenopausal women who don't actually have an indication. The honest framework is in between, and it has a name: the timing hypothesis. The right time to start HRT depends on (1) whether you have a clinical indication and (2) where you are in the timing window. Both conditions matter. This article walks through both.
By the end you'll know which of the four timing scenarios you're in, what the actual evidence is for the cardiovascular, bone, and brain effects of HRT depending on when you start it, and what to do if you're past the window. The framework is the one used by menopause specialists and the major society guidelines — not the one your primary-care doc learned in 2002 from a misread WHI headline.
Hodis 2016 ELITE (NEJM): early-initiation HRT slowed coronary atherosclerosis progression. Late-initiation did not.
The Early versus Late Intervention Trial with Estradiol (ELITE) randomized 643 postmenopausal women to either oral estradiol (with vaginal progesterone for women with a uterus) or placebo, and stratified them into two groups: those within 6 years of menopause (early initiation) and those at least 10 years past menopause (late initiation). The primary endpoint was carotid intima-media thickness — a measure of subclinical atherosclerosis progression. After ~5 years, the early-initiation group on estradiol showed significantly slower progression of atherosclerosis than placebo. The late-initiation group showed no difference. This was the first randomized trial designed specifically to test the timing hypothesis. It was published in the New England Journal of Medicine, settled a decade of controversy, and is the trial the 2022 NAMS Position Statement, the AHA scientific statement, and the Endocrine Society Guideline all cite as primary evidence for early initiation.
Citations: Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016;374(13):1221-1231. PMID: 27028912 · Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: WHI. JAMA. 2017;318(10):927-938. PMID: 28898378 · Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009;122(11):1016-1022. PMID: 19370675 · NAMS 2022 Position Statement on Hormone Therapy. Menopause. 2022;29(7):767-794. PMID: 35797481.
The 4 timing scenarios — find yours
Most women asking when to start HRT fit into one of four scenarios. The right answer for "when" depends almost entirely on which one you're in. Skim the four cards, find the closest match, and the rest of the article is about the evidence behind that recommendation.
1. Perimenopausal with significant symptoms
Still having periods (regular or irregular) but with hot flashes, night sweats, sleep disruption, mood changes, or QoL impact. The "wait until you've gone 12 months without a period" advice is outdated. NAMS 2022 and the Endocrine Society Guideline both endorse perimenopausal HRT for symptomatic women.
2. Recently menopausal (<10 yrs) with symptoms
Past your final menstrual period by less than 10 years AND under 60, with hot flashes, GSM, sleep disruption, mood, or QoL impact. This is the cleanest indication. Inside the timing window with a clinical indication — the cardiovascular, bone, and symptom-relief math all line up.
3. Recently menopausal without symptoms
Inside the window but largely asymptomatic. Conversation centers on bone density (especially with low BMD or family history), cardiovascular risk, and family/early-menopause history. Less black-and-white. NAMS 2022 allows HRT for prevention of osteoporosis with appropriate risk profile.
4. >10 years post-menopause, no prior HRT
Initiating de novo systemic HRT outside the window. The Hodis 2016 ELITE trial showed no cardiovascular benefit in this group; the Manson 2017 WHI follow-up showed neutral-to-negative signal. Usually not first-line. Important exception: vaginal estrogen for GSM is appropriate at any age (minimal systemic absorption).
If you fit scenario 1 or 2, the timing math is firmly on your side and the conversation is about which HRT preparation, not whether. If you fit scenario 3, the conversation is more individualized — bone, cardiovascular, family-history factors weigh heavily. If you fit scenario 4 and you have not previously been on HRT, current consensus is that systemic HRT is usually not first-line; vaginal estrogen for GSM is still appropriate, and a continuation conversation is different from a fresh-initiation one. Our companion article on signs you need HRT drills into the symptom side of the indication.
What "recently menopausal" actually means
Three definitions matter for the timing math, and conflating them is one of the most common sources of confusion in this conversation.
Natural menopause is defined as 12 consecutive months without a menstrual period. Your "menopause date" is retrospective — it's the date 12 months back from your final menstrual period (FMP). The average age in the United States is 51. Anything before 40 is premature menopause; 40-45 is early menopause; both warrant earlier and longer HRT than typical postmenopause for bone, cardiovascular, and cognitive protection (per the 2022 NAMS Position Statement).
Surgical menopause is bilateral oophorectomy (removal of both ovaries). Your menopause date is the date of surgery. If surgical menopause happens before age 45, current consensus is to remain on estrogen therapy at least until the average age of natural menopause (~51), unless contraindicated.
Primary ovarian insufficiency (POI) is loss of ovarian function before age 40. Treatment is closer to physiologic replacement than to standard postmenopausal HRT — and dosing is generally higher and longer than for natural-menopause HRT for the same long-term-protection reasons.
"Recently menopausal" in the context of the timing hypothesis means within 10 years of your menopause date. So a woman who became menopausal at 51 is inside the window through age 61. A woman who had surgical menopause at 42 is inside the window through 52, but she should be treated like the early-menopause population — longer therapy is generally appropriate. Our piece on perimenopause vs menopause and our article on surgical menopause and POI walk through these definitions in more detail.
The cardiovascular timing math (in plain English)
The single most important reason "when to start HRT" matters is cardiovascular. The cardiovascular effects of estrogen therapy depend dramatically on when you start it. Here is the timeline of how the evidence developed.
In 2002, the Women's Health Initiative (WHI) reported that combined estrogen + progestin (Prempro) increased cardiovascular events relative to placebo. The headline was that "HRT causes heart attacks." The trial enrolled women whose average age was 63 — most of them more than 10 years past menopause. The result was applied indiscriminately to all postmenopausal women, including women in their 50s with active vasomotor symptoms. HRT prescribing in the United States dropped by roughly 70% over the next decade. Many women who would have benefited went without.
In the years that followed, multiple WHI reanalyses (Manson 2007, Manson 2013, Manson 2017) split the original cohort by age and time since menopause. The pattern that emerged was unambiguous. Women who started HRT under 60 or within 10 years of menopause showed a favorable cardiovascular profile — a non-significant trend toward fewer coronary events and a significant reduction in all-cause mortality. Women who started HRT after 60 or more than 10 years post-menopause showed the opposite — neutral-to-increased cardiovascular events. The 2002 headline had averaged across both groups and reported the average; the average hid the fact that one group was helped and another harmed.
The Hodis 2016 ELITE trial directly tested this hypothesis with a fresh randomization. The early-initiation group on oral estradiol showed slower coronary atherosclerosis progression than placebo (significant on carotid intima-media thickness imaging). The late-initiation group showed no benefit. The trial is the cleanest randomized evidence we have for the timing hypothesis. Salpeter et al. 2009 had already shown the same pattern in a Bayesian meta-analysis of 23 RCTs (mortality reduced by ~30% in HRT users under 60).
One important refinement: the cardiovascular signal for transdermal estrogen (patches, gels, body cream) is even more favorable than for oral estrogen, because oral estrogen passes through the liver first and increases certain clotting factors. Transdermal estrogen bypasses that first-pass effect. The 2022 NAMS Position Statement and the Endocrine Society Guideline both note transdermal as preferred over oral for women with cardiovascular or thrombotic risk factors. For most women starting HRT today inside the window, transdermal is the default, with the caveat that compounded body cream, transdermal patch, and transdermal gel are all reasonable forms — the format choice is about preference and tolerability. Our deep dive on HRT types explained walks through every formulation, and our companion piece on bioidentical vs synthetic HRT resolves the lingering vocabulary confusion.
The bone timing math
Bone loss accelerates sharply in the first 5 years after menopause. Estrogen loss removes the brake on osteoclast activity (the cells that break down bone), and a woman can lose 10-15% of her bone mass in this window. After year 5, bone loss continues but at a slower rate. The clinical implication: the first 5 years post-menopause is the highest-leverage window for bone-protective intervention, and HRT initiated in that window is the most effective single intervention available.
The WHI long-term follow-up (Manson 2017) confirmed the bone benefit was real and durable: women who took HRT during the trial had significantly fewer hip fractures than placebo. The FDA approved indications for estrogen therapy include "prevention of postmenopausal osteoporosis." Bisphosphonates and denosumab are alternatives, but they are second-line interventions for women who cannot or will not take estrogen — they don't replicate the broader symptom relief or vasomotor benefit, and they have their own side-effect profiles (osteonecrosis of the jaw, atypical femoral fracture).
Inside the window of opportunity, the bone benefit is one of the strongest reasons to start HRT — particularly for women with low baseline bone density (osteopenia or osteoporosis on DEXA), family history of fracture or osteoporosis, premature/early menopause, or surgical menopause. Outside the window, the bone benefit still exists but the cardiovascular risk-benefit math has shifted, so most women starting de novo at age 70 are pushed toward bisphosphonates instead. For broader context on what HRT actually does on a 4-12 week timeline, our HRT timeline piece covers the symptom-relief curve.
The brain / cognitive timing math
The brain story closely tracks the cardiovascular story. The most-cited "HRT causes dementia" data point — the WHIMS sub-study showing increased dementia incidence in HRT users — enrolled women age 65 and older, exactly the late-initiation group. The KEEPS-Cog and ELITE-Cog studies, which enrolled women in the early-initiation window, showed neutral-to-favorable cognitive effects. The pattern is the timing hypothesis, applied to brain.
The mechanism is mechanistically plausible. Estrogen receptors are present throughout the brain, particularly in the hippocampus (memory) and prefrontal cortex (executive function). Estrogen modulates synaptic density, vascular tone in cerebral vessels, and neuroinflammation. In a brain that has become accustomed to physiologic estrogen and has minimal vascular pathology (the under-60 brain), reintroducing estrogen behaves favorably. In a brain that has already accumulated decades of vascular pathology and silent infarcts (the over-65 brain), estrogen can interact with that pathology in unfavorable ways — potentially through pro-thrombotic effects on atherosclerotic plaques.
The current 2022 NAMS Position Statement is explicit: HRT is not recommended specifically for dementia prevention. But the timing-hypothesis pattern applies to brain outcomes too — early initiation is associated with neutral-to-favorable cognition, late initiation is not. For women experiencing perimenopausal brain fog (which is real, not psychosomatic, and tracks the same volatile-estrogen window as hot flashes), HRT inside the window often helps. Our brain fog and menopause deep dive walks through the cognitive symptom story in detail.
What if you're past the window?
If you are more than 10 years past your final menstrual period and have not previously been on HRT, the conversation changes in three ways. First, systemic HRT is usually not first-line; the cardiovascular and cognitive math has shifted to neutral-or-negative for fresh initiation. Second, vaginal estrogen for genitourinary syndrome of menopause (GSM — vaginal dryness, painful sex, recurrent UTIs) is still entirely appropriate at any age, because it produces minimal systemic absorption and acts locally — see our vaginal estrogen black box warning 2026 update for the most current FDA framing. Third, if you are already on HRT, well-tolerated, with appropriate indication and surveillance, continuation past 65 is reasonable and increasingly endorsed — continuation is more evidence-based than fresh initiation at the same age.
The honest framing for women past the window who weren't told about HRT during their early-menopause years: the evidence does not support starting de novo, but it does support a real conversation with a menopause specialist about local vaginal estrogen, bone-density screening, cardiovascular risk-factor optimization, and the broader symptom picture. The window may have closed for systemic HRT, but the conversation about menopausal health is not over.
The "I missed the window — was I supposed to start at 50 and didn't?" question. No, you weren't doing it wrong. HRT prescribing in the United States dropped 70% after the 2002 WHI headline; an entire cohort of women who would have benefited went without because their physicians (and the medical literature) hadn't yet accepted the timing-hypothesis reanalysis. The window-of-opportunity framework is now standard, but it wasn't in 2005. Knowing this matters for your daughter and your sister; it doesn't undo the past.
The timing-by-scenario evidence table
Side by side, here is what the evidence supports for each of the four timing scenarios. The "notes" column is what determines the conversation in your specific picture.
| Scenario | CV evidence | Bone evidence | Brain evidence | Notes |
|---|---|---|---|---|
| 1. Perimenopausal w/ symptoms | Favorable (timing window applies) | Pre-empts the steep 5-yr bone loss | Helps cognitive symptoms of perimenopause | Endorsed by NAMS 2022 + Endocrine Society 2015 |
| 2. <10 yrs post-meno w/ symptoms | Net favorable (Hodis 2016 ELITE) | Strong — peak bone loss window | Neutral-to-favorable (KEEPS, ELITE-Cog) | Cleanest indication; transdermal preferred |
| 3. <10 yrs post-meno asymptomatic | Generally favorable | Strong if BMD low / family hx | Neutral | Individualized; risk-factor weighted |
| 4. >10 yrs post-meno, no prior HRT | Neutral-to-negative | Still positive but less leverage | Neutral-to-negative (WHIMS pattern) | Vaginal estrogen for GSM still OK at any age |
| Continuation past 65 (already on HRT) | Continuation evidence > initiation | Maintained benefit | Maintained benefit | Periodic review with clinician; no hard cutoff |
| Surgical menopause <45 | Strongly favorable | Treat to ~age 51 minimum | Strongly favorable | Closer to replacement than supplementation |
How ClearedRx prescribes HRT inside the window
ClearedRx is a doctor-supervised HRT service for women, online. You take a one-minute quiz. A licensed physician in our network reviews your symptoms, history, and timing-hypothesis position within 24 hours. If you are inside the window of opportunity and a clinical fit, they prescribe — and your treatment ships to your door, discreetly, the same week. We prescribe both compounded and FDA-approved HRT preparations; the patient picks based on cost, format preference, and clinical fit.
For most women starting HRT today inside the window, transdermal is the default — a transdermal estradiol patch, an estradiol gel, or our compounded estrogen-and-progesterone body cream applied to thigh or arm. Oral estradiol is also an option for women without thrombotic or cardiovascular risk factors. If you have a uterus, progesterone is added (oral micronized progesterone is the standard and is also bioidentical). Cost framing the way our patients experience it: ClearedRx HRT starts at $49 per month for compounded preparations and $89 per month for FDA-approved generics, all-in (medication, doctor reviews, free shipping in all 50 states). New patients receive 50% off their first month. There are no surprise fees and no insurance paperwork. Our HRT cost comparison walks through every formulation across every channel for context.
The thing to understand about timing: every month inside the window of opportunity that you spend untreated is a month of bone loss, vasomotor symptoms, and (in the early-window scenario) cardiovascular signal you can't get back. The evidence does not endorse "wait." It endorses "start when symptoms warrant AND you are inside the window." For most of you reading this, both conditions are already true.
"Hormone therapy initiated in women younger than age 60 or within 10 years of menopause and without contraindications has a favorable benefit-risk ratio for treating bothersome vasomotor symptoms and for the prevention of bone loss in those at elevated risk." — The North American Menopause Society. 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767-794.
Map the rest of your picture before you decide
Timing is one of two pillars of the "when to start HRT" decision. The other is symptom burden — what you are actually experiencing, how it is affecting your sleep, mood, work, and relationships, and how the cluster maps to the hormonal-volatility curve. The free Menopause Symptom Score is a 60-second self-check that scores the cluster as a single hormonal-fingerprint number, and our perimenopause vs menopause piece walks through which symptom-stage maps to which treatment. Sister articles worth reading before the conversation: our signs you need HRT piece walks through the indication side; our 34 symptoms of perimenopause piece is the comprehensive symptom catalogue; our HRT side effects piece covers what to expect; our HRT timeline piece walks through the symptom-relief curve at 2 / 4 / 8 / 12 weeks; our bioidentical vs synthetic HRT piece resolves the vocabulary confusion; and our menopause statistics 2026 page has the prevalence numbers across symptoms.
Frequently asked questions
When is the best time to start HRT?
The best time to start HRT is inside the "window of opportunity" — under age 60 OR within 10 years of your final menstrual period (whichever applies first). Inside that window, randomized and observational data (Hodis 2016 ELITE; Manson 2017 WHI follow-up; Salpeter 2009 meta-analysis) show a net favorable cardiovascular profile, plus the strongest bone-protection effect. The earlier inside the window, the better the cardiovascular and bone math; perimenopausal women with significant vasomotor or quality-of-life symptoms qualify even before the 12-month-no-period menopause line.
Can I start HRT in perimenopause?
Yes. You do not have to wait until you have hit the formal definition of menopause (12 consecutive months without a period) to start HRT. The 2022 NAMS Position Statement and the 2015 Endocrine Society Guideline both endorse starting hormone therapy in perimenopause for women with significant vasomotor symptoms, sleep disruption, mood symptoms, or quality-of-life impact. The "wait until menopause" advice is outdated. The timing window — not the calendar definition — is what matters for the risk-benefit math. See our perimenopause vs menopause primer for the staging definitions.
Is it too late to start HRT at 65?
Usually yes, for de novo systemic HRT initiated for the first time, if you are also more than 10 years past your final menstrual period. The Hodis 2016 ELITE trial and the Manson 2017 WHI follow-up both showed the cardiovascular benefit seen in the early-initiation group disappears or reverses when HRT is started in older, more-than-10-years-post-menopause women. Two important exceptions: (1) vaginal estrogen for genitourinary symptoms (GSM) is appropriate at any age because it produces minimal systemic absorption, and (2) women already on HRT who are tolerating it well past 65 can usually continue with their clinician's blessing — continuation is more evidence-based than starting fresh at that age.
What is the timing hypothesis?
The timing hypothesis is the evidence-based finding that the cardiovascular effects of estrogen therapy depend heavily on WHEN the therapy is started relative to menopause. Started in the window of opportunity (under 60 or within 10 years of menopause), estrogen therapy is associated with a net favorable cardiovascular profile — fewer heart attacks, less coronary atherosclerosis progression. Started more than 10 years after menopause, the same therapy shows neutral-to-negative cardiovascular effects. The hypothesis was first proposed after the WHI was reanalyzed by age subgroup, then directly tested in the Hodis 2016 ELITE randomized trial, and is now the formal framework in the 2022 NAMS Position Statement and the AHA scientific statement on women's cardiovascular health.
Should I wait until I'm in menopause to start HRT?
No, not if you have significant symptoms. The "come back when you've stopped having periods for a year" advice is outdated. The 2022 NAMS Position Statement and the 2015 Endocrine Society Guideline both recognize perimenopausal HRT as appropriate for women with significant vasomotor symptoms, sleep disruption, or mood/QoL impact. Waiting through 4-8 years of perimenopause symptoms in the hopes of meeting a calendar definition leaves you in the most volatile-estrogen phase of the transition with no treatment. The timing window matters; the calendar boundary does not.
How long can I stay on HRT?
There is no fixed expiration date. Both the 2022 NAMS Position Statement and the 2015 Endocrine Society Guideline have moved away from the old "use the lowest dose for the shortest time" framing — current consensus is that women who continue to derive symptom relief, bone protection, or quality-of-life benefit, and who have an acceptable risk profile, can continue HRT for as long as the benefit-risk balance is favorable, including past 65 in many cases. The decision is reviewed periodically with your clinician, not at a hard age cutoff. Typical use is 5-10 years; many women appropriately use HRT longer.
Does HRT prevent osteoporosis if started early?
Yes. Bone loss accelerates sharply in the first 5 years after menopause — a window during which a woman can lose 10-15% of her bone mass. HRT initiated during this early window is the most effective intervention for preventing this rapid bone loss; it preserves bone density better than any non-hormonal alternative when started in the window of opportunity. WHI long-term follow-up (Manson 2017) and the FDA Approved Indications both list prevention of postmenopausal osteoporosis as an evidence-supported use of estrogen therapy. Started 10+ years after menopause, the bone benefit still exists but the cardiovascular risk-benefit math has shifted.
Does HRT protect the brain if started early?
The brain story tracks the cardiovascular story closely. The KEEPS-Cog and ELITE-Cog studies showed estrogen therapy started in the early-menopause window was associated with neutral-to-favorable effects on cognition, while late initiation showed neutral-to-negative effects. The largest dementia-incidence signal comes from the WHIMS sub-study, which enrolled women age 65+ — exactly the late-initiation group — and showed an increased dementia risk. Reanalyses limited to early-initiation cohorts do not reproduce that signal. The current 2022 NAMS position is that HRT is not recommended specifically for dementia prevention, but the timing-hypothesis pattern applies to brain outcomes too: early initiation is associated with neutral-to-favorable cognition; late initiation is not. Our brain fog and menopause piece covers the cognitive symptom side.
Can I start HRT after a hysterectomy?
Yes — and the math is often more favorable. Women who have had a hysterectomy do not need progesterone (since they have no uterus), so they take estrogen alone (ET, not EPT). The estrogen-only arm of the WHI actually showed a numerically lower breast cancer incidence in the treated group versus placebo and a clearly favorable cardiovascular profile when started inside the window of opportunity. If you had a surgical menopause (hysterectomy with bilateral oophorectomy) before age 45, current consensus is to remain on estrogen therapy at least until the average age of natural menopause (~51) to protect long-term bone, cardiovascular, and cognitive health, unless contraindicated. See our surgical menopause and POI piece for the dosing nuances.
Should I start HRT if I'm asymptomatic?
It is a real conversation, not a black-and-white answer. For asymptomatic women under 60 within 10 years of menopause, the 2022 NAMS Position Statement and the Endocrine Society Guideline allow HRT primarily for prevention of postmenopausal osteoporosis if other indications align — particularly in women with low bone density, family history of osteoporosis or early CVD, or premature/early menopause. For women without risk factors, low bone density, or strong family history, the symptom-free window-of-opportunity case is weaker — most clinicians would not recommend HRT solely for general "longevity" or "prevention." Discuss your specific bone, cardiovascular, and family-history picture with your clinician; the decision is individualized.
Sources & references
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE Trial). N Engl J Med. 2016;374(13):1221-1231. PMID: 27028912
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. PMID: 28898378
- Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009;122(11):1016-1022. PMID: 19370675
- Mehta JM, Chester RC, Kling JM. The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease. J Womens Health (Larchmt). 2019;28(5):705-711. PMID: 30950697
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PMID: 35797481
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. PMID: 26444994
- Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. PMID: 24084921
- Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: the KEEPS Trial. Ann Intern Med. 2014;161(4):249-260. PMID: 25069991
- Henderson VW, St. John JA, Hodis HN, et al. Cognitive effects of estradiol after menopause: ELITE-Cog. Neurology. 2016;87(7):699-708. PMID: 27421538
- Internal: HRT side effects · bioidentical vs synthetic HRT · HRT cost comparison · HRT timeline · signs you need HRT · perimenopause vs menopause · 34 symptoms of perimenopause · menopause statistics 2026 · menopause symptom score
If you're inside the window — talk to a clinician now, not later
ClearedRx prescribes evidence-based HRT — bioidentical estradiol, progesterone, or a combined cream — calibrated to your timing-hypothesis position and symptom picture, with 24-hour MD review and free shipping in all 50 states. Compounded preparations from $49/month, FDA-approved generics from $89/month. No insurance hassle. New patients save 50% on the first month.
Find out if HRT is right for me
